Table 1.

The effect of baicalin and silymarin on the antioxidant status of liver tissue in fluoxetine-treated rats

Groups	SOD (U/mg)	CAT (U/mg)	GST (U/mg)	GSH (nM/mg)	MDA (nM/mg)	AOPP (nM/mg)
1	14.04 ± 0.58	7.26 ± 0.78	2.14 ± 0.22	115.76 ± 1.74	0.68 ± 0.04	0.48 ± 0.06
2	6.357 ± 0.50a	3.17 ± 0.33a	1.29 ± 0.15a	52.12 ± 1.90a	2.07 ± 0.18a	1.12 ± 0.17a
3	7.73 ± 0.65b	3.74 ± 0.45	1.32 ± 0.17c	78.87 ± 1.52c	1.73 ± 0.16c	0.83 ± 0.12c
4	11.11 ± 0.4d	4.94 ± 0.66c	1.41 ± 0.23c	97.02 ± 1.43c	1.32 ± 0.11c	0.64 ± 0.08c
5	10.37 ± 0.46d	5.37 ± 0.47c	1.54 ± 0.11d	104.91 ± 1.88c	0.96 ± 0.07c	0.56 ± 0.06d
6	14.73 ± 0.31d	7.27 ± 0.42d	1.86 ± 0.24c	110.24 ± 1.12c	0.56 ± 0.13c	0.49 ± 0.06c
7	13.98 ± 0.3d	6.66 ± 0.63d	1.68 ± 0.10c	106.58 ± 1.98c	0.69 ± 0.08c	0.50 ± 0.09c

^aRepresents a significant difference compared with group 1, P < 0.05.

^bRepresents a significant difference compared with group 2, P < 0.05.

^cRepresents a significant difference compared with group 2, P < 0.005.

^dRepresents a significant difference compared with group 2, P < 0.0005.

The activities of biomarkers were assessed in tissue homogenate. Superoxide dismutase, catalase and glutathione-S-transferase are expressed as U/mg. Reduced glutathione, malondialdehyde and advanced oxidation protein products are expressed as nM/mg. Group 1: Control rats; group 2: Fluoxetine treated rats (10 mg/kg); group 3: Fluoxetine (10 mg/kg) + baicalin (50 mg/kg); group 4: Fluoxetine (10 mg/kg) + baicalin (100 mg/kg); group 5: Fluoxetine (10 mg/kg) + silymarin (100 mg/kg); group 6: Baicalin (100 mg/kg); group 7: Silymarin (100 mg/kg). Data represent mean ± SD, n = 6. SOD: Superoxide dismutase; CAT: Catalase; GST: Glutathione-S-transferase; GSH: Reduced glutathione; MDA: Malondialdehyde; AOPP: Advanced oxidation protein products.